They live in crowded conditions, sharing bathrooms and eating facilities where social distancing is impossible. They have high rates of asthma, diabetes and heart disease.
Many struggle with mental illness. A disproportionate number are Black and Hispanic, members of minority communities that have been hard hit by the coronavirus pandemic.
So should prisoners and other detainees be given priority access to one of the new Covid-19 vaccines?
With distribution expected to start as early as this month, public health officials are scrambling to develop guidelines for the equitable allocation of limited vaccine supplies. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention will meet on Tuesday to make initial determinations about who gets the first shots.
There is broad consensus that health care workers who treat Covid-19 patients should be first in line. Other high-priority groups include residents and employees of long-term care facilities, essential workers whose jobs keep people fed and society running, and medically vulnerable and older adults — roughly in that order.
Prison inmates are not ranked in the top tiers, even though some of the largest outbreaks have occurred in the nation’s prisons. More than 2,200 inmates were sickened and 28 people died, for example, after an outbreak in the San Quentin State Prison in California over the summer.
Yet the C.D.C. advisory committee has prioritized correctional officers and others who work in jails and prisons for the first phase of immunizations. The federal prison system will set aside its initial allotment for such employees, according to documents obtained by The Associated Press.
The discrepancy raises a chilling prospect: another prison outbreak that kills scores of inmates after the only preventive was reserved for staff. Officials at the Justice Department did not respond to a request for comment.
Now several groups, including the American Medical Association, are calling for coronavirus vaccines to be given to inmates and employees at prisons, jails and detention centers, citing the unique risks to people in confinement — and the potential for outbreaks to spread from correctional centers, straining community hospitals.
“We aren’t saying that prisoners should be treated any better than anybody else, but they shouldn’t be treated any worse than anybody else who is forced to live in a congregate setting,” said Dr. Eric Toner, co-author of a report on vaccine allocation published by the Johns Hopkins Center for Health Security.
The report lists prisoners as a priority group, Dr. Toner said, though not “at the very tiptop, but at the next tier down.”
The idea is controversial. Allocating precious medical resources to people who are serving time may be anathema to much of the public, but it is widely accepted that the nation has an ethical and legal obligation to safeguard the health of incarcerated individuals.
There is also a powerful public health argument to be made for prison vaccination: Outbreaks that start in prisons and jails may leap into the surrounding community. “Prisons are incubators of infectious disease,” Dr. Toner said.
“It’s a fundamental tenet of public health to try and stop epidemics at their source,” he added.
One approach, under consideration by the National Commission on Covid-19 and Criminal Justice, would be to prioritize vaccination only for prisoners and detainees whose medical conditions or advanced age put them at great risk should they become ill.
“This isn’t a criminal justice recommendation,” said Khalil Cumberbatch, a senior fellow at the Council on Criminal Justice, a nonpartisan group focused on criminal justice policy. “It’s a public health recommendation. The virus is not in a vacuum if it’s in a state prison.”
The United States holds some 2.3 million individuals in prisons, jails and other detention centers, incarcerating more people per capita than any other nation. That includes nearly 500,000 people who have not been convicted of a crime and are awaiting trials, according to the Prison Policy Initiative. (Some jails have taken steps to reduce overcrowding since the pandemic started.)
The figure also includes some 44,000 youngsters who are held in juvenile facilities and an estimated 42,000 in immigration detention centers.
Confused by the all technical terms used to describe how vaccines work and are investigated? Let us help:
- Adverse event: A health problem that crops up in volunteers in a clinical trial of a vaccine or a drug. An adverse event isn’t always caused by the treatment tested in the trial.
- Antibody: A protein produced by the immune system that can attach to a pathogen such as the coronavirus and stop it from infecting cells.
- Approval, licensure and emergency use authorization: Drugs, vaccines and medical devices cannot be sold in the United States without gaining approval from the Food and Drug Administration, also known as licensure. After a company submits the results of clinical trials to the F.D.A. for consideration, the agency decides whether the product is safe and effective, a process that generally takes many months. If the country is facing an emergency — like a pandemic — a company may apply instead for an emergency use authorization, which can be granted considerably faster.
- Background rate: How often a health problem, known as an adverse event, arises in the general population. To determine if a vaccine or a drug is safe, researchers compare the rate of adverse events in a trial to the background rate.
- Efficacy: A measurement of how effective a treatment was in a clinical trial. To test a coronavirus vaccine, for instance, researchers compare how many people in the vaccinated and placebo groups get Covid-19. The real-world effectiveness of a vaccine may turn out to be different from its efficacy in a trial.
- Phase 1, 2, and 3 trials: Clinical trials typically take place in three stages. Phase 1 trials usually involve a few dozen people and are designed to observe whether a vaccine or drug is safe. Phase 2 trials, involving hundreds of people, allow researchers to try out different doses and gather more measurements about the vaccine’s effects on the immune system. Phase 3 trials, involving thousands or tens of thousands of volunteers, determine the safety and efficacy of the vaccine or drug by waiting to see how many people are protected from the disease it’s designed to fight.
- Placebo: A substance that has no therapeutic effect, often used in a clinical trial. To see if a vaccine can prevent Covid-19, for example, researchers may inject the vaccine into half of their volunteers, while the other half get a placebo of salt water. They can then compare how many people in each group get infected.
- Post-market surveillance: The monitoring that takes place after a vaccine or drug has been approved and is regularly prescribed by doctors. This surveillance typically confirms that the treatment is safe. On rare occasions, it detects side effects in certain groups of people that were missed during clinical trials.
- Preclinical research: Studies that take place before the start of a clinical trial, typically involving experiments where a treatment is tested on cells or in animals.
- Viral vector vaccines: A type of vaccine that uses a harmless virus to chauffeur immune-system-stimulating ingredients into the human body. Viral vectors are used in several experimental Covid-19 vaccines, including those developed by AstraZeneca and Johnson & Johnson. Both of these companies are using a common cold virus called an adenovirus as their vector. The adenovirus carries coronavirus genes.
- Trial protocol: A series of procedures to be carried out during a clinical trial.
People held in confinement are uniquely vulnerable to the virus. Incarcerated individuals are four times more likely to become infected than people in the general population, according to a study by the criminal justice commission. Over all, Covid-19 mortality rates among prisoners are higher than in the general population.
So far, at least 200,000 inmates have already been infected with Covid-19, and at least 1,450 inmates and correctional officers have died from the virus, according to a database maintained by The New York Times.
Those numbers most likely underestimate the magnitude of the problem, because reporting requirements are spotty and vary from state to state, said Dr. Tom Inglesby, an infectious disease expert at the Johns Hopkins Bloomberg School of Public Health and another co-author of the vaccine allocation report.
In Connecticut, doctors tested over 10,000 prisoners in state prisons and jails from March to June and found that 13 percent were infected with the coronavirus, according to research published in The New England Journal of Medicine. Inmates who lived in dormitory housing were at highest risk. Older inmates and Latino inmates also were more likely than others to be infected.
Even before the pandemic, many older inmates had poor health after decades of “hard living,” said Dr. Charles Lee, president-elect of the American College of Correctional Physicians.
“From my experience, their physiological age is generally 20 years greater than their chronologic age — from drugs, from fights, from being incarcerated and homeless, and not getting health care,” Dr. Lee said.
Up to 40 percent of incarcerated adults are Black, Dr. Lee said, a group with higher rates of chronic diseases such as diabetes, hypertension and asthma.
Many argue that regardless of public health considerations, society has both legal and ethical responsibilities to protect the health of inmates.
“There are truly bad guys in prison, but the vast majority of people in prisons and jails are not what the media makes us think about — they are not mass murderers,” said Arthur Caplan, director of medical ethics at the New York University Grossman School of Medicine. “Many people are about to get released soon. Many are in for petty crimes.”
“The ethical obligation is to protect the lives of prisoners, not just see them as sources of disease,” Mr. Caplan added.
View original article here Source